RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
CardioGenics Holdings Stock

CardioGenics Holdings P/S 2024

CardioGenics Holdings P/S

0

Ticker

CGNH

ISIN

US14160X2036

WKN

A1C048

As of Sep 29, 2024, CardioGenics Holdings's P/S ratio stood at 0, a 0% change from the 0 P/S ratio recorded in the previous year.

The CardioGenics Holdings P/S history

CardioGenics Holdings Aktienanalyse

What does CardioGenics Holdings do?

The company CardioGenics Holdings Inc. is headquartered in Mississauga, Canada, and is a leading company in the field of cardiovascular disease diagnostics. The company was founded in 1997 by Walter Witoshkin, who continues to serve as CEO today. CardioGenics' business model is based on the development and marketing of solutions for fast, reliable, and cost-effective diagnosis of cardiovascular diseases. The focus is especially on the diagnosis of heart attacks and heart failure. To achieve these goals, CardioGenics has developed various divisions. The most important division is the production of in-vitro diagnostics (IVD). These are tests that are performed based on blood samples, enabling doctors to make a quick and easy diagnosis. Another important area of CardioGenics is the development of diagnostics based on immunassays. Antibodies are used to identify specific proteins in the blood that indicate a certain disease. This allows early predictions about the risk of cardiovascular diseases. In addition to the development of diagnostics, CardioGenics is also active in the field of research and development. The company works closely with academic institutions and research partners to develop and market innovative solutions in the field of diagnostics. CardioGenics' products include various IVD tests specifically developed for the diagnosis of cardiovascular diseases. One of the most important products is the QL Care Analyzer, a fully automated system for the rapid determination of Troponin I, a protein released in the blood during heart attacks. Another important product of CardioGenics is the Myo9 test. This test is an immunassay that allows doctors to determine the risk of cardiovascular diseases in certain patient groups. The test is mainly used for patients with diabetes, as they have an increased risk of cardiovascular diseases. Furthermore, CardioGenics also offers various services such as training and user support for its products. The company works closely with customers to provide them with the best possible support in the application of IVD tests and other diagnostic products. In recent years, CardioGenics has expanded its business internationally and launched its products in various countries. The company also has a strong presence at leading scientific conferences and trade fairs to showcase its products and services and share its expertise in the field of cardiovascular diagnostics. In summary, CardioGenics is an established company in the field of cardiovascular disease diagnostics. With a wide range of diagnostic products and a strong focus on research and development, the company is well positioned to continue growing and strengthen its presence in the international market. CardioGenics Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding CardioGenics Holdings's P/S Ratio

CardioGenics Holdings's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing CardioGenics Holdings's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating CardioGenics Holdings's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in CardioGenics Holdings’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about CardioGenics Holdings stock

What is the price-to-earnings ratio of CardioGenics Holdings?

The price-earnings ratio of CardioGenics Holdings is currently 0.

How has the price-earnings ratio of CardioGenics Holdings changed compared to last year?

The price-to-earnings ratio of CardioGenics Holdings has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of CardioGenics Holdings high compared to other companies?

Yes, the price-to-earnings ratio of CardioGenics Holdings is high compared to other companies.

How does an increase in the price-earnings ratio of CardioGenics Holdings affect the company?

An increase in the price-earnings ratio of CardioGenics Holdings would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of CardioGenics Holdings affect the company?

A decrease in the price-earnings ratio of CardioGenics Holdings would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of CardioGenics Holdings?

Some factors that influence the price-earnings ratio of CardioGenics Holdings are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does CardioGenics Holdings pay?

Over the past 12 months, CardioGenics Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CardioGenics Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of CardioGenics Holdings?

The current dividend yield of CardioGenics Holdings is .

When does CardioGenics Holdings pay dividends?

CardioGenics Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CardioGenics Holdings?

CardioGenics Holdings paid dividends every year for the past 0 years.

What is the dividend of CardioGenics Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is CardioGenics Holdings located?

CardioGenics Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von CardioGenics Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CardioGenics Holdings from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did CardioGenics Holdings pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of CardioGenics Holdings in the year 2023?

In the year 2023, CardioGenics Holdings distributed 0 USD as dividends.

In which currency does CardioGenics Holdings pay out the dividend?

The dividends of CardioGenics Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von CardioGenics Holdings

Our stock analysis for CardioGenics Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CardioGenics Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.